scispace - formally typeset
Open AccessJournal ArticleDOI

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Merryn Voysey, +766 more
- 06 Mar 2021 - 
- Vol. 397, Iss: 10277, pp 881-891
TLDR
The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks as discussed by the authors.
About
This article is published in The Lancet.The article was published on 2021-03-06 and is currently open access. It has received 862 citations till now. The article focuses on the topics: Booster dose & Vaccine efficacy.

read more

Citations
More filters
Journal ArticleDOI

COVID-19 in People Living with HIV: A Systematic Review and Meta-Analysis.

TL;DR: In this paper, the authors focused on determining the epidemiological characteristics, clinical signs and symptoms, blood parameters, and clinical outcomes among PLHIV who contracted COVID-19.
Posted ContentDOI

Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: a mathematical modelling analysis

TL;DR: In this paper, the authors extended a mathematical model of SARS-CoV-2 transmission across different country settings to evaluate the public health impact of potential vaccines using WHO-developed target product profiles and identified optimal vaccine allocation strategies within and between-countries to maximise averted deaths under constraints on dose supply.
Journal ArticleDOI

Adverse events following ChAdOx1 nCoV-19 Vaccine (COVISHIELD) amongst health care workers: A prospective observational study

TL;DR: A prospective observational study was conducted in a tertiary care COVID dedicated hospital of Southern India from 16 Jan - 15 Apr 2021 as discussed by the authors, where nine hundred and eighty one healthcare workers who received 2 doses (4 weeks apart) were enrolled.
Journal ArticleDOI

Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database

TL;DR: In this paper, the frequency of reported thrombotic adverse events and clinical outcomes for these three COVID-19 vaccines, namely, Moderna, Pfizer and Oxford-AstraZeneca vaccines, were determined.
References
More filters
Journal ArticleDOI

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 - 
TL;DR: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.
Journal ArticleDOI

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

TL;DR: The specific objectives of this report were to assess the safety and humoral and cellular immunogenicity of a single-dose and two-dose schedule in adults older than 55 years, and safety, as measured by the occurrence of serious adverse events.
Related Papers (5)

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 -